专为室间隔植入而优化的LINEA心脏起搏导线的安全性与性能 (STARLIGHT)
LINEA 心脏起搏导线在室间隔植入中的安全性与性能优化
The purpose of the clinical investigation is to evaluate the safety and performances of the new LINEA cardiac pacing lead, intended for placement at the interventricular septum.
研究概览
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Antoine Guihard
- 电话号码:+33 1 46 01 33 20
- 邮箱:antoine.guihard@cf.microport.com
学习地点
-
-
-
Novara、意大利
- 招聘中
- Ospedale Maggiore della Carità - AO Univ.
-
接触:
- Gabriele Dell'Era
- 邮箱:gabriele.dellera@maggioreosp.novara.it
-
Pisa、意大利
- 招聘中
- Ospedale San Cataldo CNR - Fond. Toscana G. Monasterio
-
接触:
- Gianluca Mirizzi
- 邮箱:gmirizzi@ftgm.it
-
-
-
-
-
Ghent、比利时
- 招聘中
- Ghent University Hospital
-
接触:
- Jan De Pooter
- 邮箱:jadpoote.depooter@ugent.be
-
-
-
-
-
Annecy、法国
- 招聘中
- Centre Hospitalier Annecy Genevois
-
接触:
- Pierre Frey
- 邮箱:pfrey@ch-annecygenevois.fr
-
Clermont-Ferrand、法国
- 招聘中
- CHU Clermont-Ferrand
-
接触:
- Pierre-Antoine Catalan
- 邮箱:pacatalan@chu-clermontferrand.fr
-
Grenoble、法国
- 招聘中
- CHU Grenoble
-
接触:
- Adrien Carabelli
- 邮箱:acarabelli@chu-grenoble.fr
-
Montpellier、法国
- 招聘中
- Clinique du Millénaire
-
接触:
- Nicolas Clémenty
- 邮箱:nicolas.clementy@gmail.com
-
Rouen、法国
- 招聘中
- CHU Rouen Hôpital Charles Nicolle
-
接触:
- Raphaël Al Hamoud
- 邮箱:raphael.al-hamoud@chu-rouen.fr
-
Tours、法国
- 招聘中
- Hôpital Trousseau
-
接触:
- Arnaud Bisson
- 邮箱:a.bisson@chu-tours.fr
-
-
-
-
-
Coimbra、葡萄牙
- 招聘中
- ULS de Coimbra
-
接触:
- João Ferreira
- 邮箱:joaoaferreira29@gmail.com
-
Lisbon、葡萄牙
- 招聘中
- ULS Santa Maria
-
接触:
- Nelson Cunha
- 邮箱:nelsoncunha@campus.ul.pt
-
-
-
-
-
Girona、西班牙
- 招聘中
- Hospital Universitari de Girona Doctor Josep Trueta
-
接触:
- María Emilce Trucco
- 邮箱:metrucco.girona.ics@gencat.cat
-
Granada、西班牙
- 招聘中
- Hospital Universitario Virgen de las Nieves
-
接触:
- Manuel Molina
- 邮箱:manuel.molina.lerma@gmail.com
-
Valencia、西班牙
- 招聘中
- Hospital Universitari i Politècnic La Fe
-
接触:
- Óscar Cano
- 邮箱:oscape13@hotmail.com
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion criteria (phase I and II):
- Patient indicated for cardiac pacing according to the most recent guidelines from the European Society of Cardiology (ESC)
- Patient planned for a de novo implantation of an ALIZEA, BOREA or CELEA Single Chamber (SR) or Dual Chamber (DR) pacemaker from MicroPort CRM
- Patient planned for a catheter-guided ventricular pacing lead implantation in the interventricular septum area
- Patient's pacemaker with the remote monitoring functions accepted by the patient and planned to be activated
Exclusion criteria (phase I and II):
- Patient planned for a device upgrade, or a device or a lead replacement
- Patient with a congenital heart disease, hypertrophic cardiomyopathy or infiltrative cardiomyopathy
- Patient with a Left Ventricular Ejection Fraction (LVEF) ≤ 35%
- Patient already enrolled in another clinical investigation that could confound the results of this clinical investigation (e.g., clinical investigations involving intra-cardiac device)
- Patient having a contraindication for cardiac pacing system implantation (i.e. patient implanted with a defibrillator, patient for whom a single dose of steroid eluted by the pacing lead (e.g., dexamethasone sodium phosphate) is contraindicated, patient implanted with a tricuspid replacement heart valve, with prior tricuspid valve intervention or with a significant tricuspid valve disease that may lead to future replacement heart valve surgery)
- Patient with a life expectancy of less than 2 years
- Minor age patient (i.e. under 18 years of age)
- Incapacitated patient, under guardianship, kept in detention, refusing to cooperate or not able to understand the purpose of this clinical investigation
- Non-menopausal women
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:LINEA心脏起搏导线
|
Use of LINEA cardiac pacing lead and delivery catheter for implantation of pacemaker |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
LINEA lead complication free rate at 3 months
大体时间:3 months after implantation
|
Proportion of patients free from complication related to the LINEA lead. A complication is defined as a SADE with a probable or causal relationship to the LINEA lead which triggered an additional invasive intervention or resulted in patient death |
3 months after implantation
|
|
LINEA lead pacing threshold amplitude at 3 months
大体时间:3 months after implantation
|
Mean ventricular pacing threshold amplitude |
3 months after implantation
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Success rate of LINEA lead minimum sensed amplitude
大体时间:3 months after implantation
|
Proportion of patients with minimum sensed amplitude ≥ 5 mV |
3 months after implantation
|
|
General performances of LINEA lead
大体时间:Implantation, 72 hours from implantation, 1 month, 3 months, 6 months, 18 months, 30 months and 42 months after implantation
|
Pacing threshold amplitude, impedance and minimum sensed amplitude obtained with the LINEA lead at each patient's visit. LBB pacing threshold amplitude obtained with the LINEA lead during implantation, as well as the chronaxie measurement |
Implantation, 72 hours from implantation, 1 month, 3 months, 6 months, 18 months, 30 months and 42 months after implantation
|
|
Safety of the LINEA lead
大体时间:Implantation, 72 hours from implantation, 1 month, 3 months, 6 months, 18 months, 30 months and 42 months after implantation
|
LINEA lead complication free rate over time, calculated based on number of Adverse Events and Device Deficiencies related to the lead |
Implantation, 72 hours from implantation, 1 month, 3 months, 6 months, 18 months, 30 months and 42 months after implantation
|
|
Safety of the FLEXIGO delivery catheter and the FLEXIGO slitter
大体时间:Implantation, 72 hours from implantation, 1 month, 3 months, 6 months, 18 months, 30 months and 42 months after implantation
|
FLEXIGO catheter complication free rate, calculated based on number of Adverse Events and Device Deficiencies related to the catheter or the slitter |
Implantation, 72 hours from implantation, 1 month, 3 months, 6 months, 18 months, 30 months and 42 months after implantation
|
|
LINEA lead implantation success rates
大体时间:Implantation
|
Proportion of LINEA leads implanted in the interventricular septum and meeting or not LBBAP criteria |
Implantation
|
|
Lead and delivery catheter implantation time
大体时间:Implantation
|
Total procedural time and total fluoroscopic time of each implantation |
Implantation
|
|
LINEA lead and FLEXIGO delivery catheter and slitter implantation usability
大体时间:Implantation
|
Handling scores based on a specific questionnaire (scale Very poor/Poor/Acceptable/Good/Very good) |
Implantation
|
|
Right Ventricular Autothreshold performances
大体时间:3 months after implantation
|
- Accuracy - Comparison between the manual ventricular pacing threshold performed by a physician and the in-clinic ventricular pacing threshold provided by the RVAT function at the same pulse width and during the same on-site patient's visit |
3 months after implantation
|
|
Evolution of LBBAP capture over time
大体时间:18 months after implantation
|
- LBBAP capture evolution with analyses of ECGs (i.e. V6 R-wave peak time and V6-V1 interpeak interval) and LBBAP criteria collected |
18 months after implantation
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Early outcome - Absence of Unanticipated Serious Adverse Device Effect (USADE) related to LINEA lead
大体时间:1 month after implantation
|
Proportion of patients free from USADE. Any event caused by use of the LINEA lead or any accessory packaged with the lead, will be considered as an ADE related to the LINEA lead. The endpoint evaluation will be based on an independent safety events adjudication from a Clinical Events Committee (CEC), based on investigational site reporting |
1 month after implantation
|
|
Early outcome - LINEA lead pacing threshold amplitude at 1 month
大体时间:1 month after implantation
|
Mean ventricular pacing threshold amplitude |
1 month after implantation
|
|
Early outcome - Other LINEA lead and FLEXIGO delivery catheter safety and performance
大体时间:1 month after implantation
|
- Implantation success rate - Proportion of LINEA lead successfully implanted at the interventricular septum and fulfilling or not LBBAP success criteria according to the operator's decision |
1 month after implantation
|
|
Early outcome - Other LINEA lead and FLEXIGO delivery catheter safety and performance
大体时间:1 month after implantation
|
- Short term electrical performances variation - Pacing threshold variation between implantation and 1 month, and electrical performances of the LINEA lead (pacing threshold, impedance and minimum sensed amplitude) |
1 month after implantation
|
|
Early outcome - Other LINEA lead and FLEXIGO delivery catheter safety and performance
大体时间:1 month after implantation
|
- Complication free rate - Proportion of patients free from complication related to the LINEA lead. A complication is defined as a SADE with a probable or causal relationship to the LINEA lead which triggered an additional invasive intervention or resulted in patient death |
1 month after implantation
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.